Compare Enveric Biosciences Inc (ENVB) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs McDonald's Corp — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while McDonald's Corp trades at $272.03 (market cap $188.25B). The key difference: McDonald's Corp is far larger — about 35385.3× Enveric Biosciences Inc's market cap, and McDonald's Corp pays a 2.81% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | MCD | |
|---|---|---|
Market Cap | $5.32M | $188.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $341.06 |
52-Week Low | $1.28 | $264.54 |
Enterprise Value | $408.82K | $241.96B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
McDonald's (MCD) trades at $268.94, down 1.35% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, including a 31.62% net income margin and consistent revenue growth, reaching $26.89B in 2025. Recent news highlights the company's 'McDonald's NEXT' strategy focusing on automation and menu innovation to counter competition and inflation pressures.
The outlook remains positive with a consensus price target of $326.36, implying 21% upside, supported by 59.68% analyst buy ratings. Key risks include inflationary cost pressures on franchisee margins and high long-term debt of $38.42B. Earnings momentum is mixed, with a Q2 2026 estimate of $3.33 EPS to watch.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
